BN
|
HealthAI Desk•1 views

Beta-Blockers After Heart Attack: Study Questions Lifelong Use

A new study in the New England Journal of Medicine found that stopping beta-blockers in stable heart attack survivors did not raise risks of death, recurrent heart attacks, or heart failure hospitalizations compared to continued use. This supports 2023 guidelines from major cardiology associations that question lifelong beta-blocker therapy for patients without recent cardiac events. Experts argue that for those with good heart function, discontinuation could minimize side effects and reduce long-term costs. However, decisions must be personalized, and additional global research is needed to validate these findings. The South Korean-based study involved over 2,500 patients and was presented at an American College of Cardiology conference.

Ad slot
Beta-Blockers After Heart Attack: Study Questions Lifelong Use

New research indicates that discontinuing beta-blockers in stable heart attack survivors may not increase risks of death or recurrent events, challenging the long-standing practice of lifelong medication.

Evolving Treatment Guidelines

  • Updated 2023 guidelines from the American Heart Association and American College of Cardiology no longer recommend routine long-term beta-blocker therapy for patients without a recent heart attack.
  • Dr. Manesh Patel of Duke University notes that advances like angioplasty and cholesterol medications have shifted the evidence base, allowing for potential therapy de-escalation in stable patients.

Landmark Study Results

  • A study published in the New England Journal of Medicine followed over 2,500 stable heart attack patients in South Korea for approximately three years.
  • Participants were randomized to either stop or continue beta-blockers after at least one year of use.
  • Key outcomes:
    • 7.2% in the discontinuation group vs. 9% in the continuation group experienced death, recurrent heart attack, or heart failure hospitalization.
    • Death rates: 2.4% vs. 3.4%; recurrent heart attacks: 2.3% vs. 2.6%; heart failure hospitalizations: ~2% in both groups.
  • Slight increases in blood pressure and heart rate occurred after discontinuation but remained within safe ranges on average.
Ad slot

Expert Insights

  • Dr. Joseph Ravenell of NYU Langone Health emphasizes potential cost savings and improved quality of life by reducing lifelong medication burden.
  • Dr. Valentin Fuster of Mount Sinai Fuster Heart Hospital states that beta-blockers may be unnecessary for patients with good ventricular function, and practice patterns are already shifting.

Patient and Practical Considerations

  • Beta-blockers commonly cause side effects such as fatigue, dizziness, and dry mouth, which can impact adherence.
  • Decisions to discontinue should involve shared decision-making between doctors and patients, with careful monitoring.
  • The study supports considering stopping beta-blockers for appropriately selected stable patients without heart failure or left ventricular dysfunction.

Global Research Needs

  • Conducted solely in South Korea, the study requires replication in other countries, including the U.S., to confirm generalizability.
  • Optimal timing for discontinuation remains uncertain and likely varies individually, necessitating further investigation.
Ad slot